{"id":48930,"date":"2022-09-28T18:01:42","date_gmt":"2022-09-28T16:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/"},"modified":"2022-09-28T18:01:42","modified_gmt":"2022-09-28T16:01:42","slug":"global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/","title":{"rendered":"Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5654033\/global-cell-and-gene-therapy-cgt-growth?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=shp5pt&amp;utm_campaign=1756283+-+Global+Cell+and+Gene+Therapy+(CGT)+Growth+Opportunities%3A++Internal+Capabilities+for+GMP-grade+Plasmid+Manufacturing+Amongst+Other+Avenues+for+Growth&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">&#8220;Global Cell and Gene Therapy (CGT) Growth Opportunities&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220928005834\/en\/1585907\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220928005834\/en\/1585907\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis study examines the global cell and gene therapy (CGT) market. It highlights revenue forecasts and key growth opportunities for CGT market participants based on the evolution of their business models and strategic approaches as well as investments and regulations. The study segments the market by product (cell therapy, gene-modified cell therapy, and gene therapy), and it also focuses on subsegments (allogeneic versus autologous; ex vivo versus in vivo). Market forecasts run from 2022 through 2027, and they capture key market developments, such as capacity expansion, mergers and acquisitions, and extension of services offerings set to impact overall CGT market growth.\n<\/p>\n<p>\nAs CGT moves from ultra-rare indications to more common indications, the rapid expansion of manufacturing capabilities to support the commercial requirements of these diseases will become a necessity. The migration from paper-based data to the digital format will connect individual patient supply chain data with individual patient clinical data and incorporate it into the overall analysis.\n<\/p>\n<p>\nTime and speed will become crucial factors to stay ahead of the competition and reap the resulting benefits. The success of CGT in prevalent diseases, such as diabetes and stroke, will be the game changer during the forecast period and lead to new market access models.\n<\/p>\n<p>\n<strong>The research service also covers the following topics:<\/strong>\n<\/p>\n<ul>\n<li>\nMarket and Pipeline Snapshot\n<\/li>\n<li>\nKey Trends and Value Chain Analysis\n<\/li>\n<li>\nCGT Investment and M&amp;A Snapshot\n<\/li>\n<li>\nCGT Reimbursement Snapshot\n<\/li>\n<li>\nCGT Regulatory Snapshot\n<\/li>\n<li>\nDrivers and Restraints\n<\/li>\n<li>\nRecent Acquisitions and Capacity Expansion by Major Bio-CDMOs\n<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong>\n<\/p>\n<p>\n<strong>1. Strategic Imperatives<\/strong>\n<\/p>\n<ul>\n<li>\nWhy Is It Increasingly Difficult to Grow?\n<\/li>\n<li>\nThe Strategic Imperative 8T\n<\/li>\n<li>\nThe Impact of the Top 3 Strategic Imperatives on the Global CGT Industry\n<\/li>\n<li>\nGrowth Opportunities Fuel the Growth Pipeline EngineT\n<\/li>\n<li>\nKey Highlights\n<\/li>\n<\/ul>\n<p>\n<strong>2. Growth Opportunity Analysis<\/strong>\n<\/p>\n<ul>\n<li>\nScope of Analysis\n<\/li>\n<li>\nSegmentation\n<\/li>\n<li>\nDefinitions\n<\/li>\n<li>\nGrowth Metrics\n<\/li>\n<li>\nGrowth Drivers\n<\/li>\n<li>\nGrowth Restraints\n<\/li>\n<li>\nForecast Assumptions\n<\/li>\n<li>\nRevenue Forecast\n<\/li>\n<li>\nRevenue Forecast by Product\n<\/li>\n<li>\nRevenue Forecast Analysis\n<\/li>\n<li>\nRevenue Forecast by Region\n<\/li>\n<li>\nRevenue Forecast Analysis by Region\n<\/li>\n<li>\nCompetitive Environment\n<\/li>\n<li>\nRevenue Share\n<\/li>\n<li>\nRevenue Share Analysis\n<\/li>\n<\/ul>\n<p>\n<strong>3. Growth Environment<\/strong>\n<\/p>\n<ul>\n<li>\nKey Approved CGTs Until Q1 202 &#8211; Upcoming Regulatory Approvals in the US and the EU\n<\/li>\n<li>\nPipeline Snapshot\n<\/li>\n<li>\nGene Therapy and Genetically Modified Cell Therapies: Pipeline Snapshot\n<\/li>\n<li>\nCell Therapies: Pipeline Snapshot\n<\/li>\n<li>\nCGT for Cancer: A Snapshot\n<\/li>\n<\/ul>\n<p>\n<strong>4. Key Trends and Value Chain Analysis<\/strong>\n<\/p>\n<ul>\n<li>\nCGT Value Chain\n<\/li>\n<li>\nCGT Stakeholder Ecosystem\n<\/li>\n<li>\nTraditional Drugs versus CGT Business Models\n<\/li>\n<li>\nEvolving CGT Business Model: Orchestrated Collaborations between Stakeholders across the Value Chain\n<\/li>\n<li>\nKey CGT Stakeholders&#8217; Portfolio Strategies\n<\/li>\n<li>\nCGT Value Chain: Evolving Role of Stakeholders in Digitalization\n<\/li>\n<li>\nWinning Strategies for CGT Companies\n<\/li>\n<\/ul>\n<p>\n<strong>5. CGT Investment and M&amp;A Snapshot<\/strong>\n<\/p>\n<ul>\n<li>\nKey Trends Driving Investment, Expansion, Partnerships, and M&amp;As\n<\/li>\n<li>\nTrends in CGT Investment, 2021\n<\/li>\n<li>\nNotable Start-up Financing, 2021\n<\/li>\n<li>\nNotable M&amp;As, 2021-Q1 2022\n<\/li>\n<\/ul>\n<p>\n<strong>6. CGT Reimbursement Snapshot<\/strong>\n<\/p>\n<ul>\n<li>\nCurrent Reimbursement Approach for CGTs: US and EU5\n<\/li>\n<li>\nCurrent Reimbursement Approach for CGTs: APAC\n<\/li>\n<li>\nExamples of Innovative CGT Reimbursement Models\n<\/li>\n<\/ul>\n<p>\n<strong>7. CGT Regulatory Snapshot<\/strong>\n<\/p>\n<ul>\n<li>\nCurrent Formal Regulatory Meetings with US and EU Regulatory Agencies\n<\/li>\n<li>\nApproval Exemptions for CGT\n<\/li>\n<li>\nEarly Access Programs for CGT: Facilitated Approval\n<\/li>\n<li>\nEarly Access Programs for CGT: Priority Review\n<\/li>\n<li>\nEarly Access Programs for CGT: Priority Designation\n<\/li>\n<li>\nEarly Access Programs for CGT: Orphan Drug Designation\n<\/li>\n<li>\nRegulatory Risk Assessment in Early Development\n<\/li>\n<li>\nChina&#8217;s Regulatory Environment has Drastically Evolved and Became Supportive for CGT Development, Leading to the Expansion of the Domestic CGT Industry\n<\/li>\n<\/ul>\n<p>\n<strong>8. Growth Opportunity Analysis, Cell Therapy<\/strong>\n<\/p>\n<ul>\n<li>\nGrowth Metrics, Cell Therapy\n<\/li>\n<li>\nRevenue Forecast: Cell Therapy\n<\/li>\n<li>\nRevenue Forecast by Source\n<\/li>\n<li>\nRevenue Forecast Analysis\n<\/li>\n<\/ul>\n<p>\n<strong>9. Growth Opportunity Analysis, Gene Therapy<\/strong>\n<\/p>\n<ul>\n<li>\nGrowth Metrics, Gene Therapy\n<\/li>\n<li>\nRevenue Forecast: Gene Therapy\n<\/li>\n<li>\nRevenue Forecast by Technology\n<\/li>\n<li>\nRevenue Forecast Analysis\n<\/li>\n<\/ul>\n<p>\n<strong>10. Growth Opportunity Analysis, Gene-modified Cell Therapy<\/strong>\n<\/p>\n<ul>\n<li>\nGrowth Metrics, Gene-modified Cell Therapy\n<\/li>\n<li>\nRevenue Forecast: Gene-modified Cell Therapy\n<\/li>\n<li>\nRevenue Forecast by Source\n<\/li>\n<li>\nRevenue Forecast Analysis\n<\/li>\n<\/ul>\n<p>\n<strong>11. Growth Opportunity Universe<\/strong>\n<\/p>\n<ul>\n<li>\nGrowth Opportunity 1: Internal Capabilities for GMP-grade Plasmid Manufacturing\n<\/li>\n<li>\nGrowth Opportunity 2: Early Adoption of RWE to Facilitate CGT Approval and Access\n<\/li>\n<li>\nGrowth Opportunity 3: Application of CRISPR\/Cas9 to Develop Allogeneic Cell-based Immuno-oncology Therapies\n<\/li>\n<li>\nGrowth Opportunity 4: Scalable Bioreactors and Cryopreservation Solutions\n<\/li>\n<\/ul>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/5654033\/global-cell-and-gene-therapy-cgt-growth?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=shp5pt&amp;utm_campaign=1756283+-+Global+Cell+and+Gene+Therapy+(CGT)+Growth+Opportunities%3A++Internal+Capabilities+for+GMP-grade+Plasmid+Manufacturing+Amongst+Other+Avenues+for+Growth&amp;utm_exec=como322prd\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/fu3qu7<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;&#116;&#x6f;&#x3a;&#112;&#x72;&#x65;&#115;&#x73;&#x40;r&#x65;&#x73;e&#x61;&#114;c&#x68;&#97;n&#x64;&#109;a&#x72;&#107;e&#x74;&#115;&#46;&#x63;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x65;&#x73;&#x73;&#64;&#114;&#101;&#115;ear&#x63;&#x68;&#x61;&#x6e;&#x64;&#x6d;&#97;&#114;&#107;ets&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<p>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Cell and Gene Therapy (CGT) Growth Opportunities&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This study examines the global cell and gene therapy (CGT) market. It highlights revenue forecasts and key growth opportunities for CGT market participants based on the evolution of their business models and strategic approaches as well as investments &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48930","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Cell and Gene Therapy (CGT) Growth Opportunities&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This study examines the global cell and gene therapy (CGT) market. It highlights revenue forecasts and key growth opportunities for CGT market participants based on the evolution of their business models and strategic approaches as well as investments ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-28T16:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220928005834\/en\/1585907\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2022-09-28T16:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/\"},\"wordCount\":734,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005834\\\/en\\\/1585907\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/\",\"name\":\"Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005834\\\/en\\\/1585907\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-09-28T16:01:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005834\\\/en\\\/1585907\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005834\\\/en\\\/1585907\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Global Cell and Gene Therapy (CGT) Growth Opportunities&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This study examines the global cell and gene therapy (CGT) market. It highlights revenue forecasts and key growth opportunities for CGT market participants based on the evolution of their business models and strategic approaches as well as investments ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-28T16:01:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220928005834\/en\/1585907\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth &#8211; ResearchAndMarkets.com","datePublished":"2022-09-28T16:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/"},"wordCount":734,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928005834\/en\/1585907\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/","name":"Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928005834\/en\/1585907\/21\/logo.jpg","datePublished":"2022-09-28T16:01:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220928005834\/en\/1585907\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220928005834\/en\/1585907\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-cell-and-gene-therapy-cgt-growth-opportunities-internal-capabilities-for-gmp-grade-plasmid-manufacturing-amongst-other-avenues-for-growth-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Cell and Gene Therapy (CGT) Growth Opportunities: Internal Capabilities for GMP-grade Plasmid Manufacturing Amongst Other Avenues for Growth &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48930","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48930"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48930\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48930"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48930"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48930"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}